Medtronic pulls down between $700 million and $750 million from Infuse alone, analysts estimate. “So it’s up to the physician to determine when to use our product,” Cragle wrote in an email. Medtronic spokesman Steve Cragle told MassDevice in July that the company hasn’t “heard any feedback from our customers that they are reducing their expected use.” Infuse, Cragle told us, is a “physician-pull product,” meaning that Medtronic reps don’t actively promote it and aren’t compensated for any Infuse sales. “It is disappointing to find out Medtronic is not looking out for the best interests of the patient, but for own its financial interests.”Įnglish’s complaint accuses Medtronic of fraudulently misrepresenting the device’s risks and of improperly promoting and marketing Infuse for off-label uses, according to documents filed with the U.S. “I trusted Medtronic with my life,” English said in prepared remarks. But the rhBMP-2 embedded in the device allegedly caused ectopic bone growth that compressed nerves and required two revision surgeries to remove the out-of-control bone growth. The of Lake Worth, Fla., woman was implanted with an Infuse device in August 2007, according to court documents. Now Jennifer English is the latest in what’s likely to become a long line of plaintiffs to file personal injury suits against the Fridley, Minn.-based medical device colossus.
#MEDTRONIC INFUSE LAWSUIT SETTLEMENT AMOUNTS FREE#
Sign up to get our free newsletters delivered straight to your inbox
Senate are each conducting probes into the bone morphogenetic compound and its Fridley, Minn.-based maker’s marketing practices. Its investigation found problems with 13 studies by MDT-sponsored physicians, all of which downplayed or omitted the rates of adverse events associated with the protein, known as recombinant human bone morphogenetic protein-2.Īlthough the furor ignited by the study eventually died down on Wall Street (where analysts warned of a possible 3-cent-per-share dip in overall profits), Medtronic and Infuse are under intense scrutiny elsewhere. In June, the journal took the unprecedented step of devoting an entire issue to the Infuse controversy. (NYSE: MDT), after the Spine Journal revealed serious concerns about the device’s safety this summer. Personal injury lawsuits over its controversial Infuse bone-growth protein are beginning to pile up for Medtronic Inc.
0 kommentar(er)
